Analytical Data
-
Gene name
Hamster FGF21
- Application
-
Species
Rat
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
Q8VI80
-
Expression Region
Ala29~Ala207
-
Molecular Weight
25kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Fibroblast Growth Factor 21 (FGF21) is a crucial metabolic regulator involved in various physiological processes, including glucose and lipid metabolism, thermogenesis, and energy homeostasis. In the context of obesity and metabolic disorders, FGF21 has gained significant attention due to its potential therapeutic effects. Recent studies highlight the role of FGF21 in promoting insulin sensitivity and reducing body weight, making it a promising candidate for treating metabolic diseases. Research involving the construction of recombinant FGF21 proteins in hamsters provides a novel model for exploring the biological functions and therapeutic applications of this protein. By employing hamster models, researchers can investigate the unique responses of FGF21 in a species that shares similarities with human metabolic physiology. The development of recombinant hamsters expressing FGF21 allows for the detailed study of its signaling pathways and mechanisms of action, which can lead to advancements in metabolic disorder treatments. Additionally, understanding the specific interactions of FGF21 within hamster biology may offer insights into its applicability in human medicine, paving the way for potential clinical applications in managing obesity and type 2 diabetes. The ongoing research on hamster-derived FGF21 is essential for unraveling the complexities of its role in metabolism and could contribute significantly to the development of effective therapeutic strategies.
